Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hubei Biocause Pharmaceutical Co Ltd
EPS (Diluted)
Hubei Biocause Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
China Life Insurance Co Ltd
SSE:601628
|
EPS (Diluted)
¥5
|
CAGR 3-Years
68%
|
CAGR 5-Years
25%
|
CAGR 10-Years
16%
|
|
|
Ping An Insurance Group Co of China Ltd
SSE:601318
|
EPS (Diluted)
¥7
|
CAGR 3-Years
6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
New China Life Insurance Company Ltd
SSE:601336
|
EPS (Diluted)
¥11
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
15%
|
|
|
S
|
Sunshine Insurance Group Co Ltd
HKEX:6963
|
EPS (Diluted)
¥0
|
CAGR 3-Years
12%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Hubei Biocause Pharmaceutical Co Ltd
Glance View
Hubei Biocause Pharmaceutical Co., Ltd began its journey in the health sector by positioning itself strategically in the pharmaceutical industry. With its headquarters set in the Hubei Province of China, this company has intricately woven itself into the fabric of modern healthcare. Primarily, it thrives by developing, manufacturing, and distributing a variety of pharmaceutical products including both traditional and modern-medicine drugs. The journey of Biocause is punctuated by its research-driven approach, which focuses on innovation and quality control across its production lines, ensuring it stays at the forefront of pharmaceutical advancements. Revenue generation for Hubei Biocause predominantly comes from the sale of medications and healthcare products, but the company's financial tapestry is more diversified. It has explored opportunities by extending its business horizon beyond pharmaceuticals, tapping into other ventures such as insurance services. This diversification has enabled Biocause to stabilize its financial structure and mitigate risk, leveraging its steady pharma income to branch into realms that complement its healthcare base. Alongside, their strategic partnerships and alliances further bolster their market position, allowing for a broadened geographical reach and a more substantial impact on the sectors they operate within. Thus, Hubei Biocause crafts a story not only of pharmaceutical excellence but of strategic breadth that spawns wider market opportunities.
See Also
What is Hubei Biocause Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
-0.2
CNY
Based on the financial report for Sep 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's EPS (Diluted) amounts to -0.2 CNY.
What is Hubei Biocause Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
-300%
Over the last year, the EPS (Diluted) growth was -300%.